FDA Brief

Warning letters Drugs

FDA warning letter to

AmLion Toothpaste Mfg. Sdn. Bhd.

High riskIssued Nov 17, 2023Posted Nov 21, 2023Center for Drug Evaluation and Research | CDER

FDA cites AmLion Toothpaste in Malaysia for CGMP failures, including no testing of glycerin and sorbitol for DEG/EG; firm stays on import alert.

What happened

FDA inspected AmLion's drug manufacturing facility in Petaling Jaya, Selangor, Malaysia, from July 10 to 14, 2023, and found significant violations of CGMP (current good manufacturing practice, the FDA rules for how drugs must be made). The company had not tested incoming ingredients for identity, including glycerin and sorbitol, which can be contaminated with DEG or EG (industrial chemicals that have caused fatal poisonings worldwide), and had relied instead on supplier questionnaires. FDA had already placed the firm on Import Alert 66-40 on August 18, 2023, after records it submitted showed these DEG/EG control problems, and it remains on that alert, which allows FDA to refuse entry of its products into the United States.

What FDA found

  1. The firm did not test incoming ingredients to confirm identity and did not verify that its suppliers' test results were reliable, relying on supplier questionnaires instead.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm did not run the USP identity test that detects DEG and EG on each lot of high-risk ingredients such as glycerin and sorbitol before use.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The quality unit lacked authority and oversight: its procedures were inadequate, in-process quality control staff reviewed and approved batch records while reporting to general managers, not the quality unit, and unplanned deviations were not documented.

    21 CFR 211.22
  4. The stability program was inadequate, did not test active ingredients, impurities, or degradation products, and stored stability samples in a room without temperature or humidity control.

    21 CFR 211.166(a)
  5. Manufacturing processes were not validated, and investigators saw white residue and what appeared to be rust on product contact surfaces of equipment labeled as clean.

    21 CFR 211.100(a)
  6. The same types of problems were cited after inspections ending June 4, 2015 and March 2, 2018, showing remediation was not sustained.

What FDA wants

FDA asks the firm to respond in writing within 15 working days describing corrections and prevention steps, and to provide DEG and EG test results for retained high-risk component lots (or retained finished product) within 30 calendar days, along with risk assessments for products still within expiry and remediation plans for its quality unit, stability program, and process validation.

Who should pay attention

  • brands and distributors that buy finished toothpaste or OTC drugs from this contract manufacturer
  • US importers and own-label retailers sourcing OTC drug products from Malaysia
  • quality teams at other OTC manufacturers that rely on supplier questionnaires instead of identity testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  2. Thomas Brunner Hygiene GmbH

    Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

    High risk
  3. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  4. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk